Sepsis & Inflammation

Sepsis occurs in response to an infection. When sepsis is not recognised early and managed promptly, it can lead to septic shock, multiple organ failure and death.

For 2017, it was estimated that it had affected 49 million individuals and was related to approximately 11 million potentially avoidable deaths worldwide. 

Antimicrobial resistance (AMR) further complicates sepsis management across all settings, particularly in high-risk populations, such as neonates and patients in intensive care units (ICUs).* 

Clinically it is challenging to decide when and how to treat sepsis.

Despite the scale of the issue, there is a need for routine testing to enable the more specific detection and prioritisation of sepsis treatment, as current biomarkers focus mainly on detecting inflammation. A successful test to profile the risk of sepsis could therefore improve treatment, enable more timely, appropriate interventions and reduce costs.

A promising new biomarker - P Complex** 

P Complex is an acute phase protein whose levels and form rise during severe infections in humans.

A test to measure and profile this novel biomarker has the potential to ‘stage’ the risk level of patients developing severe sepsis and septic shock, and its use to determine treatment.